statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Looking Into Emergent BioSolutions's Recent Short Interest

Emergent reported quarterly earnings of $0.59 per share which beat the analyst consensus estimate of losses of 83 cents by 171.08%.
read more...

Emergent BioSolutions Reports Blockbuster Q1 Results, Raises Guidance: What's Going On With The Stock?

Futures Rise As Dovish Fed Boosts Sentiment, Reverse Bizarre Post-Powell Slide

 After a bizarre reversal when US stocks first slumped and then dumped after Powell's very dovish FOMC...

Futures Rise As Dovish Fed Boosts Sentiment, Reverse Bizarre Post-Powell Slide

Investors eyeing a purchase of Emergent BioSolutions Inc (EBS) shares, but tentative about paying the going market price of 2.33/share, might benefit from considering selling puts among the...

Commit To Purchase Emergent BioSolutions At $2, Earn 37.8% Annualized Using Options

Appoints Abigail Abbey Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of DirectorsWARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE...

Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

As the first-ever U.S. Food and Drug Administration (FDA) approved over-the-counter (OTC) naloxone in 2023, Emergent is working to expand access with NARCAN Nasal Spray and build on its longstanding...

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN  Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

GAITHERSBURG, Md., March 25, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that the U.S. Food and Drug Administration (FDA) has listed No Action Indicated or NAI...

Emergent BioSolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility

Emergent Biosolutions Non-GAAP EPS of -$0.77 misses by $0.45, revenue of $276.6M beats by $2.6M...

Emergent Biosolutions Non-GAAP EPS of -$0.77 misses by $0.45, revenue of $276.6M beats by $2.6M

Fourth Quarter 2023 Total Revenues of $277 million, which aligned our Full Year to the mid-point of guidanceFull Year 2023 Total Revenues of $1.05 billion, which was the mid-point of guidanceFourth...

Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results

This is a signal that EBS's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Emergent Biosolutions (EBS, $3.41) RSI Indicator left the overbought zone on March 05, 2024

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Watchers	4,658
52-Wk Low	$1.42
52-Wk High	$9.96

Volume	2.76M
52-Wk High	$9.96
52-Wk Low	$1.42

Period	Estimated	Reported	Surprise	Result
Q2'24	-$0.95	--	--	N/A
Q1'24	-$0.98	$0.59	160.20%	BEAT
Q4'23	$1.67	-$0.77	-146.11%	MISSED
Q3'23	-$0.22	--	--	N/A
Q2'23	-$0.65	-$1.06	-63.92%	MISSED

EBS Emergent Biosolutions Inc

About

Feed

News

Sentiment

Earnings

Fundamentals